We are live on ! Find out more
MVM

Medicxi Ventures Management Portfolio holdings

AUM $982M
1-Year Est. Return 210.17%
This Fund
S&P 500
This Quarter Est. Return
+2.54%
1 Year Est. Return
+210.17%
3 Year Est. Return
+787.54%
5 Year Est. Return
+404.19%
10 Year Est. Return
–
AUM
$529M
AUM Growth
+$157K
Cap. Flow
+$35.5M
Cap. Flow %
6.71%
Top 10 Hldgs %
100%
Holding
5
New
1
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
RAPT
RAPT Therapeutics
RAPT
+$35.5M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNTA
1
DELISTED
Centessa Pharmaceuticals
CNTA
$334M 63.2%
19,963,157
– –
NAMS icon
2
NewAmsterdam Pharma
NAMS
$3.25B
$73.7M 13.94%
2,869,565
– –
PHAT icon
3
Phathom Pharmaceuticals
PHAT
$708M
$60.6M 11.46%
7,464,572
– –
RAPT
4
DELISTED
RAPT Therapeutics
RAPT
$35.3M 6.68%
+2,794,000
New +$35.5M
AURA icon
5
Aura Biosciences
AURA
$725M
$25M 4.72%
3,039,892
– –

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
PCM
Politan Capital Management New York $985M AUM 3.12% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
FFS
Forge Financial Services Edmond, Oklahoma $987M AUM 14.12% 1-Year Est. Return
PCM
Polymer Capital Management New York $988M AUM 56.33% 1-Year Est. Return
RCG
Rock Creek Group Washington, District of Columbia $988M AUM 8.89% 1-Year Est. Return

Medicxi Ventures Management's Q4 2024 Portfolio in Review

As of Q4 2024, Medicxi Ventures Management held 5 positions worth $529M, up 0.03% from $529M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Medicxi Ventures Management deployed $35.5M of net new capital in Q4 2024, opening 1 new position. Its largest new stake was RAPT Therapeutics: 2,794,000 shares worth $35.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Medicxi Ventures Management's largest Q4 2024 buy was RAPT Therapeutics: 2,794,000 shares worth $35.3M.
  • Medicxi Ventures Management's ten largest holdings make up 100% of its $529M portfolio in Q4 2024.
  • Medicxi Ventures Management opened 1 new position and closed 0 in Q4 2024.
  • Medicxi Ventures Management's portfolio value rose 0.03% quarter-over-quarter to $529M.

Based on Medicxi Ventures Management's 13F filing for Q4 2024, filed 23 Jan 2025.